Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two major investor conferences in August and September 2026, providing a platform to discuss the company's business developments and engage with the investment community. President and CEO Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 from 1:30 p.m. to 1:55 p.m. ET. The company will also hold one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16.
These appearances come at a critical time for Tonix as it leverages its commercial infrastructure to maximize the potential of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company is also conducting Phase 2 clinical trials to evaluate TONMYA's efficacy in major depressive disorder and acute stress disorder, expanding its therapeutic reach. Additionally, Tonix's CNS portfolio includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In the immunology space, the company is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
The investor conferences provide a venue for Tonix to highlight its strategic progress and future milestones. By engaging with analysts and investors, the company aims to convey the value of its diversified pipeline and the commercial momentum of TONMYA. The fireside chat and one-on-one meetings offer opportunities for in-depth discussions about the company's clinical programs, regulatory pathways, and market opportunities.
Tonix's focus on central nervous system (CNS) and immunology treatments addresses significant unmet medical needs. The approval of TONMYA marked a major milestone, and the company is now concentrating on maximizing its commercial potential while advancing additional indications. The Phase 2 trials for major depressive disorder and acute stress disorder could open substantial new markets if successful. Meanwhile, the immunology pipeline, particularly TNX-1500, holds promise for improving outcomes in organ transplantation, a field with significant challenges.
Investors will be keen to hear updates on these programs, as well as any insights into the company's financial health and strategic partnerships. The conferences also serve as a barometer for investor sentiment and can influence the company's stock performance. For Tonix, these appearances are not just about presenting; they are about building confidence and demonstrating the long-term potential of its science.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
